Moleculin Details Adaptive 45-Patient Phase 3 MIRACLE AML Trial Progress
Moleculin released a new CEO Corner segment outlining its adaptive Phase 3 MIRACLE Study evaluating AnnAraC in 45 relapsed or refractory AML patients, with interim unblinding planned after initial dosing. Enrollment and dosing are progressing on schedule, and treatment of the first cohort is expected to conclude soon.
1. CEO Corner Segment Release
Moleculin has published its latest CEO Corner segment featuring Walter Klemp, providing detailed insights into corporate developments, clinical progress, and strategic initiatives. The platform is intended to enhance stakeholder visibility into pivotal programs and upcoming milestones.
2. MIRACLE Study Design and Enrollment
The MIRACLE Study is an adaptive Phase 3 trial of Annamycin combined with cytarabine (AnnAraC) for relapsed or refractory acute myeloid leukemia, initiated with a 45-patient cohort. The trial protocol, developed with FDA input, will undergo interim unblinding after treating these initial subjects to assess safety and efficacy.
3. Interim Unblinding and Regulatory Path
After completion of dosing in the first cohort, the study will conduct unblinded analyses to inform the most efficient regulatory strategy. Data from this interim review will guide potential modifications to dosing, enrollment targets, or submission pathways with the FDA and foreign regulators.
4. Pipeline Context and Next Steps
This Phase 3 effort follows encouraging overall survival results from the Phase 1B/2 MB-106 study, which exceeded historical benchmarks in this difficult patient population. Moleculin continues to advance its pipeline, including WP1066 for solid tumors and WP1122 for viral and cancer indications, while preparing for upcoming data readouts and financing requirements.